Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
01 Fevereiro 2024 - 12:00PM
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a
developmental stage biopharmaceutical company focused on developing
novel formulations and drug delivery systems for traditional
therapeutics and psychedelic treatments, today announced updates
for its strategic 2024 focus for its clinical pipeline. The Company
is advancing a diversified portfolio of four drugs targeting three
health areas: mental health, chronic pain, and neurology.
“This year we are prioritizing clinical development of our
post-traumatic stress disorder (PTSD) therapeutic, SPC-15, in
collaboration with Columbia University, and we plan to submit a
Pre-Investigational New Drug Application (IND) to the U.S. Food and
Drug Administration (FDA) by the end of the second fiscal quarter
in 2024,” said Eric Weisblum, CEO of Silo. “Each of our novel
therapeutics target underserved diseases with limited treatment
options where we believe we can deliver quality medical care and
make an impact.”
Silo’s lead program, SPC-15, is an intranasal prophylactic
treatment for the treatment of PTSD and stress-induced anxiety
disorder, an underserved market with few approved drugs. A
dose-ranging non GLP study of SPC-15 is in progress, with a final
validation report expected in the first half of 2024. With PTSD
affecting 3.5%1 of U.S. adults and few approved drugs, SPC-15's
method of action could offer a new and much-needed treatment
solution.
Silo's next prioritized program is SP-26, an innovative
non-opioid chronic pain solution, developed as an injectable and
dissolvable time-release ketamine-loaded implant for fibromyalgia,
utilizing the subcutaneous injection method. As a self-administered
treatment, SP-26 holds the potential to be the first at-home
ketamine treatment approved for chronic pain management.
Silo's collaboration with Columbia University has also produced
SPC-14, a nascent Alzheimer’s disease therapeutic. With initial
positive results from animal studies and more data expected in
2024, Silo believes SPC-14 represents an encouraging development in
Alzheimer’s disease research.
SPU-16, targeting multiple sclerosis (MS), is being developed in
collaboration with the University of Maryland, Baltimore (UMB). The
novel homing peptide is designed to cross the blood-brain barrier
and target damaged tissue and inflammation.
Silo plans to utilize the FDA’s streamlined 505(b)(2) pathway
for drug approval. This approach, allowing the inclusion of
external safety and efficacy data in INDs, is expected to expedite
the approval process and can reduce development costs
significantly. Through its collaborations with Columbia University
and UMB, Silo aims to leverage this pathway for each of SPC-15,
SP-26, and SPC-14.
Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage
biopharmaceutical company developing novel therapeutics that
address underserved conditions including stress-induced psychiatric
disorders, chronic pain conditions, and central nervous system
(CNS) diseases. Silo focuses on developing traditional therapies
and psychedelic treatments in novel formulations and drug delivery
systems. The Company’s lead program, SPC-15, is an intranasal
treatment targeting PTSD and stress-induced anxiety disorders.
SP-26 is a time-release ketamine-loaded implant for fibromyalgia
and chronic pain relief. Silo’s two preclinical programs are
SPC-14, an intranasal compound for the treatment of Alzheimer’s
disease, and SPU-16, a CNS-homing peptide targeting multiple
sclerosis (MS). Silo’s research and development programs are
conducted through collaborations with Columbia University and the
University of Maryland, Baltimore. For more information, visit
www.silopharma.com and connect on social media at LinkedIn, X, and
Facebook.
Forward-Looking
Statements
This news release contains "forward-looking statements" within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
identified by the use of words “could”, “believe”, “anticipate”,
“intend”, “estimate”, “expect”, “may”, “continue”, “predict”,
“potential”, and similar expressions that are intended to identify
forward-looking statements. Such statements involve known and
unknown risks, uncertainties, and other factors that could cause
the actual results of Silo Pharma, Inc. (“Silo” or “the Company”)
to differ materially from the results expressed or implied by such
statements, including changes to anticipated sources of revenues,
future economic and competitive conditions, difficulties in
developing the Company’s technology platforms, retaining and
expanding the Company’s customer base, fluctuations in consumer
spending on the Company’s products and other factors. Accordingly,
although the Company believes that the expectations reflected in
such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct. The
Company disclaims any obligations to publicly update or release any
revisions to the forward-looking information contained in this
presentation, whether as a result of new information, future
events, or otherwise, after the date of this presentation or to
reflect the occurrence of unanticipated events except as required
by law.
Contact 800-705-0120 investors@silopharma.com
1 American Psychiatric Association: What is Posttraumatic Stress
Disorder?
Silo Pharma (NASDAQ:SILO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Silo Pharma (NASDAQ:SILO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024